The DOI matches its Crossref record; 587 of the 587 references it cites were found in a registry or an index.
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Open accessAbstract
Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
Lee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812801106 · Cited by 289
RetractedZhu, K., Xiao‐Long, M., & Zhang, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17985 · Cited by 97
RetractedDas, S., Mukherjee, P., Chatterjee, R., Jamal, Z., & Chatterji, U. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0409 · Cited by 81
RetractedJoshi, N., Hajizadeh, F., Dezfouli, E. A., Zekiy, A. O., Nabi‐Afjadi, M., Mousavi, S. M., Hojjat‐Farsangi, M., Karpisheh, V., Mahmoodpoor, A., Hassannia, H., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119369 · Cited by 52
RetractedXiao, Y., Deng, T., Su, C., & Shang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.6076 · Cited by 47
RetractedZhang, K., Chen, D., Wang, X., Zhang, S., Wang, J., Gao, Y., & Yan, B. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12010385 · Cited by 27
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Metadata
- Authors
- Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 93
- Pages
- 101205
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W4385325206
- Cited by
- 294
- References
- 587
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. https://app.cochat.ai/papers/10.1016/j.mam.2023.101205
- The paper
- Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023). Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Molecular Aspects of Medicine. https://doi.org/10.1016/j.mam.2023.101205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
